Literature DB >> 9083334

Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour-conditioned medium.

N J Brown1, M W Reed.   

Abstract

Leucocyte interactions with the cremaster muscle microcirculation in vivo were investigated in response to culture medium conditioned with different cell types in 25 adult male Swiss mice. Animals were divided into five groups. Three groups received ex vivo fluorescently labelled lymphokine activated killer (LAK) cells systemically and had either tumour (murine melanoma K1735)-conditioned medium (TCM), fibroblast (murine 3T3)-conditioned medium (FCM) or fresh culture medium administered topically to the cremaster muscle. In the two remaining groups, the host leucocytes were labelled fluorescently by systemic administration of acridine red, and either TCM or FCM was applied topically to the cremaster muscle. There was an immediate but transient increase in the frequency of rolling and adherent LAK cells, and a subsequent (90-120 min later) increase in rolling and adherent host leucocytes, demonstrating temporal differences in the response to topical administration of TCM. These increases in contact with the vascular endothelium occurred in all vessel types, venules, arterioles and capillaries, with the greatest response observed in the venules. The FCM and normal culture medium did not affect the distribution and localization of either LAK cells or host leucocytes. These data suggest that there are one or more soluble tumour-specific chemoattractants for leucocytes present in the conditioned medium. The mouse cremaster muscle microcirculation is therefore a useful model to investigate the mechanism of leucocyte-endothelium interactions in tumour biology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083334      PMCID: PMC2222733          DOI: 10.1038/bjc.1997.171

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels.

Authors:  P Basse; R B Herberman; M Hokland; R H Goldfarb
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Rapid leukocyte accumulation by "spontaneous" rolling and adhesion in the exteriorized rabbit mesentery.

Authors:  E Fiebig; K Ley; K E Arfors
Journal:  Int J Microcirc Clin Exp       Date:  1991-05

3.  An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy.

Authors:  S Baez
Journal:  Microvasc Res       Date:  1973-05       Impact factor: 3.514

4.  Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.

Authors:  C A McIntyre; K Chapman; S Reeder; M S Dorreen; L Bruce; S Rodgers; K Hayat; T Schreenivasan; E Sheridan; B W Hancock
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

5.  Comparison between 125IUdR and 51Cr as cell labels in investigations of tumor cell migration.

Authors:  P Basse; P Hokland; M Hokland
Journal:  Int J Rad Appl Instrum B       Date:  1990

6.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

Authors:  S E Ettinghausen; E H Lipford; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

9.  Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation.

Authors:  A Sasaki; R J Melder; T L Whiteside; R B Herberman; R K Jain
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

10.  Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.

Authors:  K Hayat; S Rodgers; L Bruce; R C Rees; K Chapman; S Reeder; M S Dorreen; E Sheridan; T Sreenivasan; B W Hancock
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  1 in total

1.  Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.

Authors:  N J Brown; S Ali; M W Reed; R Wiltrout; R C Rees
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.